Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YB7F
|
|||
| Former ID |
DIB020458
|
|||
| Drug Name |
MT-II
|
|||
| Synonyms |
Melanotan II; 121062-08-6; Melanotan-II; Melanotan (MT)-II; Melatonan; Melanotan II acetate salt; CHEMBL430239; L-Lysinamide, N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-7)-peptide; (3S,6S,9R,12S,15S,23S)-12-((1H-imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide; Melanotan -Ii; C50H69N15O9; Asp5; Melanotan II acetate; D-Phe7; melanotan II; MTII; MTII Melanotan-II; Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Female sexual arousal dysfunction [ICD-11: HA01.1; ICD-9: 302.7] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C50H69N15O9
|
|||
| Canonical SMILES |
CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N)NC(=O)C
|
|||
| InChI |
1S/C50H69N15O9/c1-3-4-16-36(59-29(2)66)44(69)65-41-25-42(67)55-20-11-10-18-35(43(51)68)60-47(72)39(23-31-26-57-34-17-9-8-15-33(31)34)63-45(70)37(19-12-21-56-50(52)53)61-46(71)38(22-30-13-6-5-7-14-30)62-48(73)40(64-49(41)74)24-32-27-54-28-58-32/h5-9,13-15,17,26-28,35-41,57H,3-4,10-12,16,18-25H2,1-2H3,(H2,51,68)(H,54,58)(H,55,67)(H,59,66)(H,60,72)(H,61,71)(H,62,73)(H,63,70)(H,64,74)(H,65,69)(H4,52,53,56)/t35-,36-,37-,38+,39-,40-,41-/m0/s1
|
|||
| InChIKey |
JDKLPDJLXHXHNV-MFVUMRCOSA-N
|
|||
| CAS Number |
CAS 121062-08-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14890081, 14939041, 16659180, 44423271, 50064256, 50112577, 57335280, 80867774, 93815086, 103481530, 104068740, 104121488, 104407428, 123389854, 134340245, 134343469, 135048952, 135652308, 137274328, 139116892, 142227675, 144240042, 152134073, 152344279, 152344459, 162177756, 162222552, 164828419, 184605715, 187072143, 227296747, 244119246, 249719041, 251915695, 251917045, 252156616, 252351544
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanocortin receptor (MCR) | Target Info | Inhibitor | [2] |
| Melanocortin receptor 1 (MC1R) | Target Info | Agonist | [2], [3] | |
| Melanocortin receptor 3 (MC3R) | Target Info | Agonist | [2], [4] | |
| Melanocortin receptor 4 (MC4R) | Target Info | Agonist | [1], [2], [5] | |
| Melanocortin receptor 5 (MC5R) | Target Info | Agonist | [6] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Melanogenesis | ||||
| Pathway Interaction Database | Syndecan-3-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66. | |||
| REF 2 | Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35. | |||
| REF 3 | Design of potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and 10. J Med Chem. 1989 Jan;32(1):174-9. | |||
| REF 4 | Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat. Eur J Pharmacol. 1999 Aug 13;378(3):249-58. | |||
| REF 5 | Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry. 2000 Dec 5;39(48):14900-11. | |||
| REF 6 | The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. Eur J Pharmacol. 2002 Apr 12;440(2-3):141-57. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.